Informação sobre produto
AZD 8329 is an orally active, small-molecule inhibitor of the enzyme fatty acid synthase (FAS) that has been shown to be safe and well tolerated in clinical trials. It is currently being studied as a potential treatment for obesity, type 2 diabetes mellitus, and other metabolic disorders. AZD 8329 has a novel mechanism of action that blocks the synthesis of fatty acids, which are a major energy source in the body. This drug also inhibits adipose tissue lipolysis and suppresses appetite. The drug's effects on insulin sensitivity have not been fully elucidated, but it may represent an alternative to thiazolidinediones such as rosiglitazone because it does not appear to increase cardiovascular risk or cause edema. AZD 8329 was found to inhibit FAS activity by competitive inhibition with microglial activation in vitro with up to 95% inhibition at concentrations of 10 μM. In vivo studies demonstrated that AZD 8329 effectively reduced
Propriedades químicas
Consulta técnica sobre: 3D-BA179810 AZD 8329
Se desejar solicitar um orçamento ou fazer uma encomenda, por favor, adicione os produtos ao seu carrinho e depois solicite um orçamento ou encomenda a partir do carrinho. É mais rápido, mais barato e poderá beneficiar-se dos descontos e outras vantagens disponíveis.
